Literature DB >> 30358858

Blood mRNA Measurement (NETest) for Neuroendocrine Tumor Diagnosis of Image-Negative Liver Metastatic Disease.

Anna Malczewska1, Lisa Bodei2, Mark Kidd3, Irvin M Modlin4.   

Abstract

Context: Early cancer detection is critical to optimize treatment. This is particularly problematic in neuroendocrine tumors (NETs), which exhibit an ∼5-year diagnostic delay due to covert symptoms, limitations in imaging, and circulating biomarkers. Despite development of continuous monitoring strategies utilizing advanced modalities [CT/MRI or 68Gallium positron emission tomography (PET)/CT] or a repertoire of monoanalyte biomarkers [e.g., chromogranin A (CgA), pancreastatin, serotonin], detection of minimal residual disease or microrecurrence remains elusive. Emerging molecular liquid biopsies (e.g., NETest) provide a substantially improved threshold for disease detection. Case Description: We describe the utility of a blood-based multigene PCR neuroendocrine measurement (NETest), which is representative of core molecular drivers of neuroendocrine tumorigenesis, to detect hepatic micrometastases in a patient with negative blood biomarkers and negative anatomical/functional imaging. The 52-year-old woman, who had undergone margin-negative resection for a NET of the ileocecal valve, developed persistently elevated NETest levels 8 months later. CT/MRI/68Gallium PET and biomarkers remained negative. Blood multigene analysis identified disease, and peptide receptor radionuclide therapy (PRRT) was undertaken. Over 9 months, NETest levels increased (conventional biomarkers/imaging remained normal). Liver biopsy was undertaken, and foci of a 3-mm NET in segment VI were histologically documented. At 3.3 years after PRRT, the disease remained as a microscopic burden and stable biomarker/68Gallium PET/MRI occult despite elevated blood levels of NET genes. Conclusions: Blood measurement of NET transcripts can identify image- and CgA-negative disease. A NET liquid biopsy strategy has clinical utility in the early identification of residual or metastatic disease and optimizes consideration of adjuvant therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30358858     DOI: 10.1210/jc.2018-01804

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  13 in total

Review 1.  Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2019-11-27       Impact factor: 4.512

2.  Early Identification of Residual Disease After Neuroendocrine Tumor Resection Using a Liquid Biopsy Multigenomic mRNA Signature (NETest).

Authors:  Irvin M Modlin; Mark Kidd; Kjell Oberg; Massimo Falconi; Pier Luigi Filosso; Andrea Frilling; Anna Malczewska; Ronald Salem; Christos Toumpanakis; Faidon-Marios Laskaratos; Stefano Partelli; Matteo Roffinella; Claudia von Arx; Beata Kos Kudla; Lisa Bodei; Ignat A Drozdov; Alexandra Kitz
Journal:  Ann Surg Oncol       Date:  2021-05-18       Impact factor: 5.344

3.  A multigenomic liquid biopsy biomarker for neuroendocrine tumor disease outperforms CgA and has surgical and clinical utility.

Authors:  I M Modlin; M Kidd; M Falconi; P L Filosso; A Frilling; A Malczewska; C Toumpanakis; G Valk; K Pacak; L Bodei; K E Öberg
Journal:  Ann Oncol       Date:  2021-08-11       Impact factor: 51.769

4.  PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest.

Authors:  Lisa Bodei; Mark S Kidd; Aviral Singh; Wouter A van der Zwan; Stefano Severi; Ignat A Drozdov; Anna Malczewska; Richard P Baum; Dik J Kwekkeboom; Giovanni Paganelli; Eric P Krenning; Irvin M Modlin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-12-14       Impact factor: 9.236

5.  Circulating Neuroendocrine Gene Transcripts (NETest): A Postoperative Strategy for Early Identification of the Efficacy of Radical Surgery for Pancreatic Neuroendocrine Tumors.

Authors:  Stefano Partelli; Valentina Andreasi; Francesca Muffatti; Marco Schiavo Lena; Massimo Falconi
Journal:  Ann Surg Oncol       Date:  2020-04-06       Impact factor: 5.344

Review 6.  Advanced Pancreatic Neuroendocrine Neoplasms: Which Systemic Treatment Should I Start With?

Authors:  Victor Rodriguez-Freixinos; Alia Thawer; Jaume Capdevila; Diego Ferone; Simron Singh
Journal:  Curr Oncol Rep       Date:  2021-05-03       Impact factor: 5.075

7.  NETest is superior to chromogranin A in neuroendocrine neoplasia: a prospective ENETS CoE analysis.

Authors:  Anna Malczewska; Kjell Oberg; Beata Kos-Kudla
Journal:  Endocr Connect       Date:  2021-01       Impact factor: 3.335

8.  The NETest liquid biopsy is diagnostic for gastric neuroendocrine tumors: observations on the blood-based identification of microscopic and macroscopic residual diseaseOK.

Authors:  A Malczewska; A Procner; A Walter; K Kusnierz; W Zajecki; H Aslanian; B Kos-Kudla
Journal:  BMC Gastroenterol       Date:  2020-07-23       Impact factor: 3.067

Review 9.  The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors.

Authors:  Anna Malczewska; Beata Kos-Kudła; Mark Kidd; Ignat Drozdov; Lisa Bodei; Somer Matar; Kjell Oberg; Irvin M Modlin
Journal:  Adv Med Sci       Date:  2019-12-13       Impact factor: 3.287

10.  Evaluation of circulating transcript analysis (NETest) in small intestinal neuroendocrine neoplasms after surgical resection.

Authors:  Faidon-Marios Laskaratos; Man Liu; Anna Malczewska; Olagunju Ogunbiyi; Jennifer Watkins; Tu Vinh Luong; Dalvinder Mandair; Martyn Caplin; Christos Toumpanakis
Journal:  Endocrine       Date:  2020-04-14       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.